Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Leukemia & lymphoma [Leuk Lymphoma] NLMUID: 9007422"" wg kryterium: JN


Tytuł:
Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry.
Autorzy:
Baggio D; Olivia Newton John Cancer Research and Wellness Centre, Austin Health, Heidelberg, Australia.
Wellard C; School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
Chung E; School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
Talaulikar D; Canberra Health, Australian Capital Territory, Canberra, Australia.
Keane C; Princess Alexandra Hospital, Woolloongabba, Australia.
Opat S; School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.; Monash Health, Clayton, Australia.
Giri P; Royal Adelaide Hospital, Adelaide, Australia.
Minson A; Peter MacCallum Cancer Centre, Melbourne, Australia.; The Royal Melbourne Hospital, Parkville, Australia.
Cheah CY; Sir Charles Gairdner Hospital, Nedlands, Australia.
Armytage T; Gosford Hospital, Gosford, Australia.
Lee D; Eastern Health, Box Hill, Australia.
Chong G; Ballarat Regional Integrated Cancer Centre, Ballarat, Australia.
Johnston A; Royal Hobart Hospital, Hobart, Australia.
Cochrane T; Gold Coast University Hospital, Southport, Australia.
Waters N; School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
Hamad N; St Vincent's Health, Darlinghurst, Australia.
Wood EM; School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
Hawkes EA; Olivia Newton John Cancer Research and Wellness Centre, Austin Health, Heidelberg, Australia.; School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2023 Mar; Vol. 64 (3), pp. 621-627. Date of Electronic Publication: 2022 Dec 21.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Lymphoma, Mantle-Cell*/pathology
Adenine/*analogs & derivatives
Adult ; Humans ; Australia/epidemiology ; Piperidines/therapeutic use ; Registries
Czasopismo naukowe
Tytuł:
Excess mortality in younger patients with myeloproliferative neoplasms.
Autorzy:
Abu-Zeinah K; School of Clinical Medicine, University of Cambridge, Cambridge, UK.
Saadeh K; School of Clinical Medicine, University of Cambridge, Cambridge, UK.
Silver RT; The Richard T. Silver, M.D. Myeloproliferative Neoplasms Center, Division of Hematology & Medical Oncology, New York, NY, USA.
Scandura JM; The Richard T. Silver, M.D. Myeloproliferative Neoplasms Center, Division of Hematology & Medical Oncology, New York, NY, USA.
Abu-Zeinah G; The Richard T. Silver, M.D. Myeloproliferative Neoplasms Center, Division of Hematology & Medical Oncology, New York, NY, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2023 Mar; Vol. 64 (3), pp. 725-729. Date of Electronic Publication: 2022 May 09.
Typ publikacji:
Letter; Research Support, Non-U.S. Gov't
MeSH Terms:
Neoplasms*
Myeloproliferative Disorders*/diagnosis
Humans ; Mutation
Raport
Tytuł:
Clinical impact of KIR haplotypes in 10/10 HLA-matched unrelated donor-recipient pairs undergoing allogeneic hematopoietic stem cell transplantation.
Autorzy:
Moyer AM; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Hashmi SK; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Kroning CM; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Patnaik M; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Litzow M; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Gastineau DA; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Hogan WJ; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Jacob EK; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Kreuter JD; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Wakefield LL; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Gandhi MJ; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2023 Mar; Vol. 64 (3), pp. 671-678. Date of Electronic Publication: 2022 Nov 30.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Hematopoietic Stem Cell Transplantation*/adverse effects
Graft vs Host Disease*/etiology
Graft vs Host Disease*/prevention & control
Humans ; Haplotypes ; Unrelated Donors ; Retrospective Studies ; HLA Antigens/genetics ; Chronic Disease ; Receptors, KIR/genetics ; Recurrence
Czasopismo naukowe
Tytuł:
Flare-up phenomenon or pseudoprogression after CAR T-cell infusion in non-Hodgkin aggressive lymphomas.
Autorzy:
Sortais C; Department of Hematology, CHU de Nantes, Nantes, France.
Cordeil S; Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.
Bourbon E; Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.
Idlhaj M; Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.
Ferrant E; Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.
Safar V; Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.
Golfier C; Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.
Lazareth A; Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.
Bouafia-Sauvy F; Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.
Tordo J; Department of Nuclear Medicine, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.
Ghesquières H; Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.; Lymphoma Immuno-biology (LIB) Research Unit, Claude Bernard Lyon 1 University, Lyon, France.
Sesques P; Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.
Bachy E; Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.; Lymphoma Immuno-biology (LIB) Research Unit, Claude Bernard Lyon 1 University, Lyon, France.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2023 Mar; Vol. 64 (3), pp. 707-711. Date of Electronic Publication: 2022 Dec 27.
Typ publikacji:
Journal Article
MeSH Terms:
Lymphoma, Non-Hodgkin*/diagnosis
Lymphoma, Non-Hodgkin*/therapy
Humans ; Immunotherapy, Adoptive/adverse effects ; T-Lymphocytes ; Antigens, CD19
Czasopismo naukowe
Tytuł:
CDK7 inhibition induces apoptosis in acute myeloid leukemia cells and exerts synergistic antileukemic effects with azacitidine in vitro and in vivo .
Autorzy:
Zhang S; Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P.R. China.; Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
Feng R; Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P.R. China.
Bai J; Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P.R. China.
Ning S; Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P.R. China.
Xu X; Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P.R. China.
Sun J; Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P.R. China.
Wu M; Department of Medical Research Center, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, P.R. China.; Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, P.R. China.
Liu H; Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P.R. China.; Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2023 Mar; Vol. 64 (3), pp. 639-650. Date of Electronic Publication: 2023 Jan 19.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Azacitidine*/pharmacology
Azacitidine*/therapeutic use
Leukemia, Myeloid, Acute*/drug therapy
Animals ; Humans ; Mice ; Apoptosis ; Cell Line, Tumor ; Cell Proliferation ; Cyclin-Dependent Kinases
Czasopismo naukowe
Tytuł:
Prognostic significance of blast immunophenotype on first post-induction bone marrow biopsy.
Autorzy:
Lontos K; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Tsagianni A; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Agha M; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Raptis A; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Hou JZ; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Farah R; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Redner RL; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Im A; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Dorritie KA; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Sehgal A; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Rossetti J; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Aggarwal N; Department of Pathology, University of Pittsburgh, School of Medicine, Pittsburgh, PA, USA.
Saul M; Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Boyiadzis M; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Bailey NG; Department of Pathology, University of Pittsburgh, School of Medicine, Pittsburgh, PA, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2023 Mar; Vol. 64 (3), pp. 750-752. Date of Electronic Publication: 2023 Feb 01.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:
Bone Marrow*/pathology
Bone Marrow Cells*/pathology
Humans ; Prognosis ; Remission Induction ; Biopsy
Czasopismo naukowe
Tytuł:
The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry.
Autorzy:
Buckstein R; Division of Medical Oncology and Hematology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada.; Department of Medicine, University of Toronto, Toronto, Canada.
Chodirker L; Division of Medical Oncology and Hematology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada.; Department of Medicine, University of Toronto, Toronto, Canada.
Yee KWL; Department of Medicine, University of Toronto, Toronto, Canada.; Cancer Clinical Research Unit, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Geddes M; Department of Medicine, Tom Baker Cancer Centre, Calgary, Canada.
Leitch HA; Division of Hematology, St. Paul's Hospital, University of British Columbia, Vancouver, Canada.
Christou G; Clinical epidemiology, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Canada.
Banerji V; CancerCare Manitoba Foundation, Winnipeg, Canada.
Leber B; Hematology Disease Site Team, Juravinski Cancer Centre, Hamilton Health Sciences, Hamilton, Canada.
Khalaf D; Hematology Disease Site Team, Juravinski Cancer Centre, Hamilton Health Sciences, Hamilton, Canada.
St-Hilaire E; Hematology Services, Centre Hospitalier Universitaire Dr. Georges-L.-Dumont, Moncton, Canada.
Finn N; Hematology Services, Centre Hospitalier Universitaire Dr. Georges-L.-Dumont, Moncton, Canada.
Nevill T; Division of Hematology, Leukemia/Bone Marrow Transplant Program of BC, BC Cancer, University of British Columbia, Vancouver, Canada.
Keating MM; Division of Hematology, Dalhousie University, Halifax, Canada.
Storring J; Hematology Division, McGill University Health Centre, Montréal, Canada.
Parmentier A; Division of Medical Oncology and Hematology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada.
Thambipillai A; Division of Medical Oncology and Hematology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada.
Tang D; Bristol Myers Squibb, Princeton, NJ, USA.
Westcott C; Celgene Inc., a Bristol-Myers Squibb Company, Mississauga, Canada.
Cameron C; Value and Evidence Division, Marketing and Market Access, EVERSANA™, Sydney, Canada.
Spin P; Value and Evidence Division, Marketing and Market Access, EVERSANA™, Sydney, Canada.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2023 Mar; Vol. 64 (3), pp. 651-661. Date of Electronic Publication: 2023 Jan 06.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Erythrocyte Transfusion*/adverse effects
Myelodysplastic Syndromes*/drug therapy
Humans ; Quality of Life ; Prospective Studies ; Registries
Czasopismo naukowe
Tytuł:
Should WE use flow cytometry to assess bone marrow involvement by lymphoma?
Autorzy:
Jurado R; Hematology Laboratory, Unitat de citometria ICO-Badalona (CITICOB), Hospital Germans Trias i Pujol, IJC, LUMN, Universitat Autònoma de Barcelona, Badalona, Spain.
Aren M; Hematology Laboratory, Unitat de citometria ICO-Badalona (CITICOB), Hospital Germans Trias i Pujol, IJC, LUMN, Universitat Autònoma de Barcelona, Badalona, Spain.
Sorigue M; Hematology Laboratory, Unitat de citometria ICO-Badalona (CITICOB), Hospital Germans Trias i Pujol, IJC, LUMN, Universitat Autònoma de Barcelona, Badalona, Spain.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2023 Mar; Vol. 64 (3), pp. 753-755. Date of Electronic Publication: 2023 Mar 08.
Typ publikacji:
Journal Article
MeSH Terms:
Lymphoma*/diagnosis
Lymphoma*/pathology
Lymphoma, Non-Hodgkin*/pathology
Humans ; Bone Marrow/pathology ; Flow Cytometry ; Immunophenotyping
Czasopismo naukowe
Tytuł:
The prognostic significance of CRLF2 expression at diagnosis in adult Ph-negative B-cell precursor acute lymphoblastic leukemia.
Autorzy:
Wang J; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Sun K; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Chen WM; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Wang X; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Li LD; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Hao Y; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Xu N; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Jiang H; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Xu LP; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Wang Y; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Zhang XH; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Huang XJ; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Jiang Q; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Qin YZ; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2023 Mar; Vol. 64 (3), pp. 698-706. Date of Electronic Publication: 2023 Jan 15.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma*/diagnosis
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma*/genetics
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/diagnosis
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/genetics
Adult ; Humans ; Prognosis ; Receptors, Cytokine/genetics ; Retrospective Studies ; Philadelphia Chromosome
Czasopismo naukowe
Tytuł:
Genetics and epigenetics of CLL.
Autorzy:
Paul P; Department of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
Stüssi G; Department of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
Bruscaggin A; Laboratory of Experimental Hematology, Institute of Oncology of Southern Switzerland, Institute of Oncology Research, Bellinzona, Switzerland.
Rossi D; Department of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.; Laboratory of Experimental Hematology, Institute of Oncology of Southern Switzerland, Institute of Oncology Research, Bellinzona, Switzerland.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2023 Mar; Vol. 64 (3), pp. 551-563. Date of Electronic Publication: 2022 Dec 12.
Typ publikacji:
Review; Journal Article
MeSH Terms:
Leukemia, Lymphocytic, Chronic, B-Cell*/diagnosis
Leukemia, Lymphocytic, Chronic, B-Cell*/genetics
Humans ; Immunoglobulin Heavy Chains/genetics ; Immunoglobulin Variable Region/genetics ; Epigenomics ; Epigenesis, Genetic ; Mutation
Czasopismo naukowe
Tytuł:
Immunogenicity of COVID-19 mRNA vaccines in patients with acute myeloid leukemia and myelodysplastic syndrome.
Autorzy:
Helfgott DC; Department of Medicine, Division of Infectious Diseases, Weill Cornell Medicine, The New York Presbyterian Hospital, New York, NY, USA.
Racine-Brzostek S; Department of Pathology and Laboratory Medicine, Translational Research Program, Weill Cornell Medicine, The New York Presbyterian Hospital, New York, NY, USA.
Short KJ; Department of Medicine, Division of Hematology and Oncology, Weill Cornell Medicine, The New York Presbyterian Hospital, New York, NY, USA.
Zhao Z; Department of Pathology and Laboratory Medicine, Translational Research Program, Weill Cornell Medicine, The New York Presbyterian Hospital, New York, NY, USA.
Christos P; Department of Biostatistics, Weill Cornell Medicine, New York, NY, USA.
Nino I; Department of Medicine, Division of Hematology and Oncology, Weill Cornell Medicine, The New York Presbyterian Hospital, New York, NY, USA.
Niu T; Department of Medicine, Division of Hematology and Oncology, Weill Cornell Medicine, The New York Presbyterian Hospital, New York, NY, USA.
Contreras J; Department of Medicine, Division of Hematology and Oncology, Weill Cornell Medicine, The New York Presbyterian Hospital, New York, NY, USA.
Ritchie EK; Department of Medicine, Division of Hematology and Oncology, Weill Cornell Medicine, The New York Presbyterian Hospital, New York, NY, USA.
Desai P; Department of Medicine, Division of Hematology and Oncology, Weill Cornell Medicine, The New York Presbyterian Hospital, New York, NY, USA.
Samuel M; Department of Medicine, Division of Hematology and Oncology, Weill Cornell Medicine, The New York Presbyterian Hospital, New York, NY, USA.
Roboz GJ; Department of Medicine, Division of Hematology and Oncology, Weill Cornell Medicine, The New York Presbyterian Hospital, New York, NY, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2023 Mar; Vol. 64 (3), pp. 662-670. Date of Electronic Publication: 2022 Oct 25.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
MeSH Terms:
COVID-19*/prevention & control
COVID-19 Vaccines*/adverse effects
Leukemia, Myeloid, Acute*/genetics
Leukemia, Myeloid, Acute*/therapy
Myelodysplastic Syndromes*/therapy
Adult ; Humans ; 2019-nCoV Vaccine mRNA-1273 ; Antibodies, Neutralizing ; Antibodies, Viral ; BNT162 Vaccine ; mRNA Vaccines ; SARS-CoV-2 ; Vaccination
Czasopismo naukowe
Tytuł:
Sudden lymphoid blast crisis after tyrosine kinase inhibitor discontinuation in chronic phase chronic myeloid leukemia: cautionary tales for appropriate molecular monitoring.
Autorzy:
Bataller A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Haddad FG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Issa GC; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sasaki K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ferrajoli A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2023 Mar; Vol. 64 (3), pp. 746-749. Date of Electronic Publication: 2023 Jan 19.
Typ publikacji:
Journal Article
MeSH Terms:
Leukemia, Myeloid, Chronic-Phase*/diagnosis
Leukemia, Myeloid, Chronic-Phase*/drug therapy
Leukemia, Myeloid, Chronic-Phase*/genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/diagnosis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/genetics
Humans ; Blast Crisis/drug therapy ; Tyrosine Kinase Inhibitors ; Protein Kinase Inhibitors/adverse effects
Czasopismo naukowe
Tytuł:
Brentuximab vedotin plus bendamustine versus platinum-based regimens as 1st salvage therapy and 'bridge' to autologous hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma.
Autorzy:
Kaloyannidis P; Adult Hematology & Stem Cell Transplantation Department, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
Al Zayer M; Adult Hematology & Stem Cell Transplantation Department, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
Al Darweesh M; Adult Hematology & Stem Cell Transplantation Department, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
Al Batran M; Adult Hematology & Stem Cell Transplantation Department, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
Al Garni A; Department of Pathology & Laboratory Medicine, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
Al Naim A; Medical Imaging Department, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
Al Hashmi H; Adult Hematology & Stem Cell Transplantation Department, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
Kanfar S; Adult Hematology & Stem Cell Transplantation Department, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2023 Mar; Vol. 64 (3), pp. 742-745. Date of Electronic Publication: 2023 Jan 11.
Typ publikacji:
Journal Article
MeSH Terms:
Hodgkin Disease*/drug therapy
Hodgkin Disease*/pathology
Hematopoietic Stem Cell Transplantation*
Immunoconjugates*/therapeutic use
Humans ; Brentuximab Vedotin ; Bendamustine Hydrochloride ; Salvage Therapy ; Neoplasm Recurrence, Local ; Transplantation, Autologous ; Stem Cell Transplantation ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Ascertaining QUAZARs: slow-motion and light-speed development of oral azacitidine and decitabine.
Autorzy:
Feld J; Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Tremblay D; Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Navada SC; Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Silverman LR; Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2023 Mar; Vol. 64 (3), pp. 525-539. Date of Electronic Publication: 2022 Nov 12.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Myelodysplastic Syndromes*/drug therapy
Myelodysplastic Syndromes*/pathology
Leukemia, Myeloid, Acute*/drug therapy
Humans ; Decitabine/therapeutic use ; Antimetabolites, Antineoplastic/therapeutic use ; Azacitidine/therapeutic use
Czasopismo naukowe
Tytuł:
Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma.
Autorzy:
Van Le H; Biometrics and Data Sciences, Bristol Myers Squibb, Princeton, NJ, USA.
Van Naarden Braun K; Translational Epidemiology, Bristol Myers Squibb, Princeton, NJ, USA.
Nowakowski GS; Hematology, Mayo Clinic, Rochester, MN, USA.
Sermer D; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Radford J; Department of Medical Oncology, The Christie NHS Foundation Trust and University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
Townsend W; Hematology, University College London Hospitals NHS Foundation Trust, London, UK.
Ghesquieres H; Department of Hematology, Hôpital Lyon Sud, Lyon, France.
Menne T; Hematology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Northumberland, UK.
Porpaczy E; Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Fox CP; Department of Clinical Hematology, Nottingham University Hospitals NHS Trust, Nottingham, UK.
Schusterbauer C; Clinical Research and Development, Celgene, a Bristol-Myers Squibb Company, Boudry, Switzerland.
Liu FF; Worldwide Health Economics and Outcomes Research CAR T, Bristol Myers Squibb, Princeton, NJ, USA.
Yue L; Statistics, Bristol Myers Squibb, Princeton, NJ, USA.
De Benedetti M; Biometrics and Data Sciences, Bristol Myers Squibb, Princeton, NJ, USA.
Hasskarl J; Cell Therapy Development, Celgene, a Bristol-Myers Squibb Company, Boudry, Switzerland.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2023 Mar; Vol. 64 (3), pp. 573-585. Date of Electronic Publication: 2023 Feb 08.
Typ publikacji:
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Lymphoma, Large B-Cell, Diffuse*/drug therapy
Humans ; Antigens, CD19 ; Immunotherapy, Adoptive/adverse effects ; Progression-Free Survival ; Propensity Score
Czasopismo naukowe
Tytuł:
Therapeutic approaches for the management of higher risk myelodysplastic syndromes.
Autorzy:
Wang C; Department of Internal Medicine, University of South Florida, Morsani College of Medicine, Tampa, FL, USA.; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Sallman DA; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2023 Mar; Vol. 64 (3), pp. 511-524. Date of Electronic Publication: 2022 Nov 25.
Typ publikacji:
Review; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Myelodysplastic Syndromes*/diagnosis
Myelodysplastic Syndromes*/etiology
Myelodysplastic Syndromes*/therapy
Leukemia, Myeloid, Acute*
Humans ; Bone Marrow ; Stem Cell Transplantation ; Risk Assessment ; Prognosis
Czasopismo naukowe
Tytuł:
A phase II study to evaluate the efficacy of low-dose rasburicase (1.5mg) in adolescent and adult acute leukemia and high-grade lymphomas with tumor lysis syndrome.
Autorzy:
Majumdar S; Medical Oncology, MS Ramaiah Medical College, Rajiv Gandhi University of Health Sciences, Bangalore, India.
Sharma N; Medical Oncology, Tata Memorial Centre, Homi Bhabha National University, Mumbai, India.
Sengar M; Medical Oncology, MS Ramaiah Medical College, Rajiv Gandhi University of Health Sciences, Bangalore, India.
Thorat J; Medical Oncology, MS Ramaiah Medical College, Rajiv Gandhi University of Health Sciences, Bangalore, India.
Nayak L; Medical Oncology, MS Ramaiah Medical College, Rajiv Gandhi University of Health Sciences, Bangalore, India.
Bonda A; Medical Oncology, Homi Bhabha Cancer Hospital & Research Centre, Tata Memorial Centre, Mumbai, India.
Bagal B; Medical Oncology, MS Ramaiah Medical College, Rajiv Gandhi University of Health Sciences, Bangalore, India.
Rajendra A; Department of Medical Oncology, Cancer Institute WIA, Adyar, Chennai, India.
Sethi A; Department of Electrical Engineering, Indian Institute of Bombay, Powai, India.
Jain H; Medical Oncology, MS Ramaiah Medical College, Rajiv Gandhi University of Health Sciences, Bangalore, India.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2023 Mar; Vol. 64 (3), pp. 628-638. Date of Electronic Publication: 2023 Mar 08.
Typ publikacji:
Clinical Trial, Phase II; Journal Article
MeSH Terms:
Tumor Lysis Syndrome*/diagnosis
Tumor Lysis Syndrome*/drug therapy
Tumor Lysis Syndrome*/etiology
Lymphoma, Non-Hodgkin*
Leukemia, Myeloid, Acute*
Adult ; Humans ; Adolescent ; Uric Acid ; Urate Oxidase/adverse effects
Czasopismo naukowe
Tytuł:
TP53 -altered higher-risk myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a distinct genetic entity with unique unmet needs.
Autorzy:
Ball S; Division of Hematology and Medical Oncology, University of South Florida/H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Loghavi S; Department of Hematopathology, MD Anderson Cancer Center, Houston, TX, USA.
Zeidan AM; Department of Internal Medicine, Section of Hematology, Yale Cancer Center, New Haven, CT, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2023 Mar; Vol. 64 (3), pp. 540-550. Date of Electronic Publication: 2022 Nov 02.
Typ publikacji:
Journal Article
MeSH Terms:
Leukemia, Myeloid, Acute*/diagnosis
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/genetics
Myelodysplastic Syndromes*/diagnosis
Myelodysplastic Syndromes*/drug therapy
Myelodysplastic Syndromes*/genetics
Myeloproliferative Disorders*
Humans ; Tumor Suppressor Protein p53/genetics ; Mutation
Czasopismo naukowe
Tytuł:
Comorbidity burden and outcomes of older adults with acute promyelocytic leukemia: a National Cancer Database analysis of 2221 patients.
Autorzy:
Dhakal P; Department of Internal Medicine, Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA, USA.
Lyden E; Department of Biostatistics, University of Nebraska Medical Center, Omaha, NE, USA.
Joshi U; Department of Internal Medicine, Rochester General Hospital, Rochester, NY, USA.
Pyakuryal A; Department of Nursing, Nobel College, Pokhara University, Kathmandu, Nepal.
Loh KP; Division of Hematology/Oncology, Department of Medicine, James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
Klepin H; Section on Hematology and Oncology, Department of Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Bhatt VR; Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.; Division of Oncology and Hematology, Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2023 Mar; Vol. 64 (3), pp. 691-697. Date of Electronic Publication: 2023 Jan 11.
Typ publikacji:
Journal Article
MeSH Terms:
Leukemia, Promyelocytic, Acute*/epidemiology
Neoplasms*
Humans ; Aged ; Comorbidity ; Multivariate Analysis
Czasopismo naukowe
Tytuł:
A phase II study of obinutuzumab in combination with ibrutinib for treatment of relapsed mantle cell lymphoma.
Autorzy:
Kim MS; Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
Banerjee T; Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
Chen A; Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
Danilov A; City of Hope National Medical Center, Duarte, CA, USA.
MacKinnon R; Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
Thurlow B; Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
Thakurta S; Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
Orand K; City of Hope National Medical Center, Duarte, CA, USA.
Degnin C; Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
Park B; Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
Spurgeon SE; Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2023 Mar; Vol. 64 (3), pp. 722-724. Date of Electronic Publication: 2022 Mar 09.
Typ publikacji:
Clinical Trial, Phase II; Letter; Research Support, Non-U.S. Gov't
MeSH Terms:
Lymphoma, Mantle-Cell*/drug therapy
Lymphoma, Mantle-Cell*/pathology
Adult ; Humans ; Neoplasm Recurrence, Local/drug therapy ; Piperidines
Raport

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies